BioSpace News Archive

Integral Molecular and Optimeos Life Sciences announce a partnership to develop next-generation mRNA and DNA therapeutics that will use antibody-based molecular targeting to direct vaccines and gene therapies to relevant tissues in a patient’s body.

Antibody drug conjugates are the new drug class which exploits the specificity of monoclonal antibodies to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.

Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty acid synthase (FASN) inhibitors, announced today that it will present additional Phase 2 data on denifanstat (formerly TVB-2640) identifying a predictive ‘metabolic signature’ in nonalcoholic steatohepatitis (NASH) patients.

Promontory Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, announced today the peer-reviewed publication of its first-in-human Phase 1 study of lead therapeutic candidate, PT-112 in the July 2022 issue of eClinicalMedicine, part of The Lancet’s Discovery Science.

Royal Philips announced the publication of its Future Health Index 2022 report: ‘Healthcare hits reset: Priorities shift as healthcare leaders navigate a changed world’.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

The industry analysis report is considered a valuable source of information about the global Hepatitis A Vaccine industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The global physiotherapy equipment market size is expected to reach USD 24.91 Billion in 2028 and register a revenue CAGR of 5.2% over the forecast period, according to the latest report by Reports and Data.

The market for regenerative medicine is witnessing increased demand owing to the emergence of stem cell technology, increase in prevalence of chronic diseases, and advancements in surgical technologies.

In recent times, immunotherapy has emerged out to be most exciting paradigm change in cancer treatment. Since its initial approval in breast cancer, it has become the standard mode of treatment for wide subtypes of breast cancer.